Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Free Cash Flow (2023 - 2025)

Upstream Bio (UPB) has 3 years of Free Cash Flow data on record, last reported at -$22.3 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 59.75% year-over-year to -$22.3 million; the TTM value through Sep 2025 reached -$122.7 million, down 120.4%, while the annual FY2024 figure was -$59.7 million, 56.77% down from the prior year.
  • Free Cash Flow reached -$22.3 million in Q3 2025 per UPB's latest filing, up from -$39.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$8.0 million in Q2 2024 and bottomed at -$41.2 million in Q1 2025.
  • Average Free Cash Flow over 3 years is -$22.3 million, with a median of -$18.8 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: fell 24.08% in 2024, then plummeted 388.29% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$16.1 million in 2023, then fell by 24.08% to -$20.0 million in 2024, then decreased by 11.58% to -$22.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$22.3 million in Q3 2025, -$39.2 million in Q2 2025, and -$41.2 million in Q1 2025.